A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis

Summary

This study aims to identify the safety and tolerability of bile acid supplementation in patients with progressive Multiple Sclerosis (MS). Participants will also be assessed for an impact of the bile acid on their immune system and gut microbiome. Half of the participants will receive the bile acid tauroursodeoxycholic acid (TUDCA) and half will receive placebo. The investigators believe participants who take TUDCA will have normalization of blood bile acid levels, a normalization of abnormal immune response and a normalization of the gut microbiome.

Timeline

Start

2018-06-19

Primary completion

2022-04-28

Completion

2022-07-05

Publications

• Ladakis DC, Harrison KL, Smith MD, Solem K, Gadani S, Jank L, Hwang S, Farhadi F, Dewey BE, Fitzgerald KC, Sotirchos ES, Saidha S, Calabresi PA, Bhargava P. Bile acid metabolites predict multiple sclerosis progression and supplementation is safe in progressive disease. Med. 2025 Mar 14;6(3):100522. doi: 10.1016/j.medj.2024.09.011. Epub 2024 Oct 23.

Drugs

Indications